0K6R Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$132.31 |
| 52 Week High | US$148.34 |
| 52 Week Low | US$89.66 |
| Beta | 0.28 |
| 1 Month Change | -5.83% |
| 3 Month Change | -3.96% |
| 1 Year Change | 26.19% |
| 3 Year Change | 36.43% |
| 5 Year Change | 44.51% |
| Change since IPO | 48.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K6R | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.6% | -2.3% | -0.7% |
| 1Y | 26.2% | -29.4% | -1.8% |
Return vs Industry: 0K6R exceeded the UK Biotechs industry which returned -29.4% over the past year.
Return vs Market: 0K6R exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0K6R volatility | |
|---|---|
| 0K6R Average Weekly Movement | 2.8% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0K6R has not had significant price volatility in the past 3 months.
Volatility Over Time: 0K6R's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,400 | Kevin Gorman | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
Neurocrine Biosciences, Inc. Fundamentals Summary
| 0K6R fundamental statistics | |
|---|---|
| Market cap | US$13.33b |
| Earnings (TTM) | US$249.70m |
| Revenue (TTM) | US$1.89b |
53.4x
P/E Ratio7.1x
P/S RatioIs 0K6R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K6R income statement (TTM) | |
|---|---|
| Revenue | US$1.89b |
| Cost of Revenue | US$604.70m |
| Gross Profit | US$1.28b |
| Other Expenses | US$1.03b |
| Earnings | US$249.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 2.48 |
| Gross Margin | 67.96% |
| Net Profit Margin | 13.23% |
| Debt/Equity Ratio | 7.6% |
How did 0K6R perform over the long term?
See historical performance and comparison